Semaglutide (Ozempic), a Glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in improving glycemic control and offering renal protection in type 2 diabetes. We present the case of a 40-year-old male with poorly controlled type 2 diabetes and early diabetic nephropathy, who experienced significant metabolic and renal improvements following semaglutide therapy. Initially, on SGLT2 inhibitors, the patient discontinued treatment due to recurrent urinary tract infections. On presentation, he exhibited hyperglycemia, dyslipidemia, proteinuria, and reduced eGFR. Semaglutide was initiated alongside metformin, gliclazide, antihypertensives, and lipid-lowering agents. Over 12 months, HbA1c improved from 9.8% to 6.1%, and urine albumin-to-creatinine ratio decreased from 267 mg/g to 34 mg/g, with improved eGFR. This case supports the renoprotective and metabolic benefits of semaglutide and highlights its potential as a therapeutic option in patients intolerant to SGLT2 inhibitors.